Small molecules simply cant make enough contact, which is why oral GLP-1 agonists were out of reach for decades
This regulatory divergence provides powerful evidence that Novo Nordisk prioritized U.S
Patients underwent a 9 week run-in period (3-week forced dose escalation followed by a 6-week dose maintenance phase) with rosiglitazone (starting at 4 mg and increasing to 8 mg/day within 2 weeks) and metformin (starting at 500 mg with increasing weekly increments of 500 mg to a final dose of 2,000 mg/day)
Following the expiry of semaglutides patent in India (March 2021, 2026), the market changed dramatically.[13][14] 40+ Indian pharma companies launched generic GLP-1 medications[12] Prices dropped by ~80% Key players include: Sun Pharma Dr
Smaller doses and more gradual dose escalation schedules can soften the impact of side effects and insulin requirement changes
Also, diet and lifestyle behavior change remain crucial even with GLP-1 medication to achieve and maintain a healthy weight and reduce health risks